BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
17.15
-0.03 (-0.17%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close17.18
Open17.19
Bid0.00 x 0
Ask0.00 x 0
Day's Range17.12 - 17.25
52 Week Range15.67 - 32.80
Volume495,674
Avg. Volume993,633
Market Cap64.345B
Beta (3Y Monthly)0.85
PE Ratio (TTM)9.30
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.81 (5.05%)
Ex-Dividend Date2019-04-29
1y Target EstN/A
Trade prices are not sourced from all markets
  • What's in Store for Bayer (BAYRY) This Earnings Season?
    Zacks14 hours ago

    What's in Store for Bayer (BAYRY) This Earnings Season?

    Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.

  • AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why
    Zacks5 days ago

    AVEO Pharmaceuticals Down More Than 40% in 90 Days: Here's Why

    AVEO Pharmaceuticals (AVEO) suffers a major hindrance as it defers its NDA filing for Fotivda in the United States.

  • Barrons.com5 days ago

    ‘Goodwill’ Write-Offs Are an Earnings Killer. How to Spot Trouble Coming.

    Companies write off “goodwill” when the value of acquired assets declines. It happened at Kraft Heinz and GE. Keep an eye on Bayer and Cigna next.

  • Are Investors Undervaluing Bayer (BAYRY) Right Now?
    Zacks6 days ago

    Are Investors Undervaluing Bayer (BAYRY) Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA
    Zacks6 days ago

    Ultragenyx's (RARE) UX007 Gets Fast Track Status by FDA

    Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.

  • Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and G-III Apparel
    Zacks11 days ago

    Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and G-III Apparel

    Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and G-III Apparel

  • Bayer says to comply with court mediation order in glyphosate case
    Reuters11 days ago

    Bayer says to comply with court mediation order in glyphosate case

    Bayer said on Friday it would comply with a U.S. federal judge's order to enter mediation with a plaintiff who claims the company failed to warn against an alleged cancer risk from its Roundup weedkiller. Bayer has seen billions wiped off its market value since August, when a first U.S. jury found Bayer liable because Monsanto, acquired by Bayer for $63 billion last year, had not warned of the alleged risk from Roundup, which is based on active ingredient glyphosate. U.S. District Judge Vince Chhabria, who presided over the first two cases in federal court, said in a filing dated Thursday that Bayer and another plaintiff, Elaine Stevick, were ordered to start confidential mediation.

  • Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon
    Zacks11 days ago

    Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon

    Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.

  • Bayer (BAYRY) Stock Moves -1.33%: What You Should Know
    Zacks12 days ago

    Bayer (BAYRY) Stock Moves -1.33%: What You Should Know

    Bayer (BAYRY) closed at $17.02 in the latest trading session, marking a -1.33% move from the prior day.

  • Reuters12 days ago

    French court finds Bayer's Monsanto liable for farmer's sickness

    PARIS/LYON (Reuters) - A French court has ruled that Monsanto was liable for the sickness of a farmer who inhaled one of its weedkillers, in another legal setback for the Bayer-owned business over health claims. In the latest stage of a decade-long legal tussle, the appeals court in Lyon on Thursday found in favour of farmer Paul Francois' claim that Monsanto's Lasso weedkiller had made him sick and that the product's labelling had been inadequate. "Mr Francois justifiably concludes that the product, due to its inadequate labelling that did not respect applicable regulations, did not offer the level of safety he could legitimately expect," the court said in its ruling.

  • Reuters12 days ago

    U.S. criticizes Vietnam ban of glyphosate herbicide imports

    Vietnam's government said in a statement that the toxic level of herbicides containing glyphosate had long been of concern, in the latest display of global worries over the product's impact on human health. Glyphosate, the chemical contained in Bayer AG's best-selling weed killer Roundup, is the target of thousands of lawsuits in the United States alleging exposure to it causes cancer. Roundup, which Bayer acquired with its $63 billion purchase of Monsanto last year, was the first to contain glyphosate, the world's most widely used weed killer.

  • Reuters12 days ago

    Bayer considers legal options after French court rules for farmer

    German chemical group Bayer said it was considering its legal options, including an appeal, after a French court ruled in favour of a farmer who blamed a weedkiller of Bayer's Monsanto unit for health problems. Thursday's ruling by an appeals court in Lyon in southeast France was the latest stage in a decade-long legal tussle between Monsanto and farmer Paul Francois, who says he fell ill after inhaling weedkiller Lasso in 2004.

  • 6 Valuable Price-to-Book Stocks to Buy as Slowdown Lurks
    Zacks12 days ago

    6 Valuable Price-to-Book Stocks to Buy as Slowdown Lurks

    P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

  • CEO sees Bayer 'massively' affected by herbicide litigation
    Reuters12 days ago

    CEO sees Bayer 'massively' affected by herbicide litigation

    Bayer's chief executive on Thursday acknowledged the German maker of pharmaceuticals and crop chemicals was facing massive challenges from a wave of lawsuits over an alleged carcinogenic effect of its Roundup weedkiller. You see it in our share price," CEO Werner Baumann said in a panel discussion at an academic business event in Cologne. Bayer has seen about 30 billion euros ($34 billion) wiped off its market value since August, when a U.S. jury found Bayer liable because Monsanto, acquired by Bayer for $63 billion last year, had not warned of weedkiller Roundup's alleged cancer risks.

  • Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA
    Zacks13 days ago

    Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA

    Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).

  • Bayer shareholder Deka joins chorus of complaints over Monsanto
    Reuters13 days ago

    Bayer shareholder Deka joins chorus of complaints over Monsanto

    One of Bayer's largest shareholders tore into the company's management on Wednesday for underestimating the legal risks of its takeover of Monsanto, setting the stage for a fiery annual general meeting after a 30 percent plunge in the shares. Bayer has seen about 30 billion euros ($34 billion) wiped off its market value since August, when a U.S. jury found Bayer liable because Monsanto had not warned of weedkiller Roundup's alleged cancer risks. There can be no talk of a successful takeover any more," Ingo Speich, the head of sustainability and corporate governance at Deka Investment, told Reuters.

  • Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
    Zacks14 days ago

    Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

    Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

  • Associated Press14 days ago

    Pharmaceuticals giant Bayer to cut 4,500 jobs in Germany

    BERLIN (AP) — Pharma and chemicals giant Bayer says it is cutting 4,500 jobs in its home market of Germany.

  • Aeglea (AGLE) Reports New Positive Data for Pegzilarginase
    Zacks15 days ago

    Aeglea (AGLE) Reports New Positive Data for Pegzilarginase

    Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.